

Regimen Reference Order – LEUK – GIMEMA IT (ALL Ph+) IT Prophylaxis

Intrathecal therapy (IT) Prophylaxis is prescribed in combination with induction oral dasatinib,
and with each cycle of blinatumomab post induction

ARIA: LEUK - [GIMEMA IT induction]

LEUK - [GIMEMA IT post-blin]

Planned Course: Intrathecal therapy (IT) on Day +14, +22, +43, +57, +85 of induction with oral dasatinib, followed by
Intrathecal therapy (IT) on Day +29 at the end of each cycle of blinatumomab (post induction)

Indication for Use: Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive (Ph+);
Newly Diagnosed

CVAD: At Provider's Discretion

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Intrathecal Therapy (IT) during Induction

ARIA: LEUK - [GIMEMA IT induction]

Proceed with treatment if:

- Platelets equal to or greater than $50 \times 10^9/L$
- INR less than 1.5
- Fibrinogen greater than 1
 - ❖ Contact Leukemia/BMT (L/BMT) Physician if parameters not met

Days +14, +43 and +85 of induction

Drug	Dose	CCMB Administration Guideline
methotrexate	12 mg	Intrathecal in 6 mL preservative free normal saline administered in L/BMT Clinic

Days +22 and + 57 of induction

Drug	Dose	CCMB Administration Guideline
cytarabine	50 mg	Intrathecal in 6 mL preservative free normal saline administered in L/BMT Clinic

Intrathecal Therapy (IT) at the end of each cycle of blinatumomab

ARIA: LEUK - [GIMEMA IT post-blin]

Proceed with treatment if:

- **Platelets equal to or greater than $50 \times 10^9/L$**
- **INR less than 1.5**
- **Fibrinogen greater than 1**
 - ❖ **Contact Leukemia/BMT (L/BMT) Physician if parameters not met**

Day +29 of Cycles 1, 3, and 5 of blinatumomab

Drug	Dose	CCMB Administration Guideline
cytarabine	50 mg	Intrathecal in 6 mL preservative free normal saline administered in L/BMT Clinic

Day +29 of Cycles 2 and 4 of blinatumomab

Drug	Dose	CCMB Administration Guideline
methotrexate	12 mg	Intrathecal in 6 mL preservative free normal saline administered in L/BMT Clinic

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

- CBC and biochemistry as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Not applicable

ADDITIONAL INFORMATION

- This Regimen Reference Order is intended for patients receiving intrathecal (IT) therapy on Days +14, +22, +43, +57 and + 85 during induction with oral dasatinib and on Day +29 after each cycle of blinatumomab post induction
- IT therapy (induction) is ordered as a separate Support protocol under GIMEMA IT Induction in the "Leukemia" folder
- IT therapy (post blinatumomab) is ordered as a separate Support protocol under GIMEMA IT post blin in the "Leukemia" folder